Moderna entities must face infringement suits, UPC rules

UPC rejects jurisdictional challenges from Moderna | Court allows two linked infringement cases over mRNA tech to move forward in The Hague | Ruling finds commercial links between Moderna entities enough to justify its jurisdiction over non-UPC territories.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

Emotional Perception: What next for patent holders?

3 March 2026 After an overwhelmingly positive Supreme Court ruling for companies working in AI, Rachel Free of CMS outlines the necessary practical steps for patent holders—including enforcement of the ‘black box’ tech, the ruling’s influence on the UPC, and how to manage related applications.

Europe

Emotional Perception exclusive: ‘We are now very much open for business’

16 February 2026 Following the UK Supreme Court’s recent landmark judgment, which ushers in a sea-change to patent law, the team behind a groundbreaking AI-related invention sit down with Sarah Speight to explain how they got here, and why the ruling changes everything.

Europe

UPC appeals court confirms ‘all-or-nothing’ rule for unitary patents

12 February 2026 The court has denied a German non-practising entity’s bid to secure unitary protection for a patent that it has asserted against Intel.

More features

DWT recruits first-chair trial litigator as latest hire in IP expansion

To cite or not to cite: How can we avoid misuse of AI in court?

Gowling WLG brings in transactions expert with UK and US experience

Emotional Perception: What next for patent holders?

LSPN Awards 2026 finalists revealed

Natera and a rival draw the line under five-year fight

SCOTUS flooded with briefs calling for reversal of ‘skinny label’ ruling

Eli Lilly escapes $278m payout in biotech licensing dispute

Moderna entities must face infringement suits, UPC rules

More on this story

Editor's picks

Editor's picks

More features